#Iceland #Reykjavik #ADHD Therapy #Amlodipine #3Z Pharmaceuticals

3Z Pharmaceuticals Unveils Landmark Study on Amlodipine as an ADHD Treatment

In a significant advancement in the field of ADHD treatment, 3Z Pharmaceuticals has published a transformative study in the journal Neuropsychopharmacology, providing compelling evidence for the use of amlodipine—a medication traditionally employed in hypertension management—as a non-stimulant therapy for ADHD. The groundbreaking findings are poised to address the current limitations in ADHD treatment, particularly the issues surrounding stimulant medications.

ADHD: Current Challenges

ADHD, or Attention Deficit Hyperactivity Disorder, affects millions worldwide. The conventional treatments primarily revolve around stimulant medications like methylphenidate, which, while effective for some patients, often come with undesirable side effects including increased anxiety, potential for abuse, and suboptimal responsiveness in a significant number of individuals. Recognizing these challenges, 3Z Pharmaceuticals has taken an innovative approach to explore alternative treatment options for ADHD.

Key Findings from the Study

The new study integrates a multifaceted approach, employing cross-species behavioral assays, Mendelian Randomization analysis, and analysis of human genetic data to underscore the therapeutic promise of amlodipine:

1. Behavioral Rescue in ADHD Models: In tests with Spontaneously Hypertensive Rats and zebrafish models, amlodipine effectively reduced hyperactivity and improved impulsivity. These results provide cross-species validation of its efficacy in addressing core ADHD symptoms.

2. Blood-Brain Barrier Penetration: Contrary to prior assumptions that calcium channel blockers might poorly penetrate the brain, examination of amlodipine revealed its ability to traverse the blood-brain barrier, where it positively modulates neuronal activity.

3. Genetic Evidence: Analyses using Mendelian Randomization linked the risk of ADHD to variations in several L-type calcium channel genes, which are direct targets of amlodipine. This genetic correlation reinforces the mechanistic underpinnings of its potential in treating ADHD.

4. Clinical Relevance in Human Populations: The study also highlighted findings from the UK Biobank, indicating that individuals with a genetic predisposition to ADHD who were treated with amlodipine reported reduced symptoms, independent of its effects on blood pressure.

Expert Commentary

Dr. Karl Karlsson, a leading neuroscientist and the CEO of 3Z Pharmaceuticals, underlined the importance of these findings, stating, "This research signifies a paradigm shift in ADHD therapeutics. Our results validate amlodipine's mechanism as a promising candidate for non-stimulant treatment options, showcasing the capabilities of our high-throughput screening and genetic modeling methods in partnership with biotx.ai. We are dedicated to advancing effective and well-tolerated ADHD therapies."

Future Directions

Building on this promising research, 3Z Pharmaceuticals is committed to developing this novel therapeutic variant towards clinical trials. The company aims to leverage amlodipine's established safety profile and its precise action mechanism in the brain to introduce an innovative alternative for individuals seeking effective ADHD treatment without the reliance on traditional stimulants.

As the study marks a significant step forward in ADHD therapy, it also opens new doors for understanding neurodevelopmental disorders, illustrating the transformative potential of repurposing existing medications for new applications in mental health treatment.

• ---

For further details, the study can be accessed through Nature.com.